Regeneron Pharmaceuticals Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 5/6
Regeneron Pharmaceuticals has a total shareholder equity of $29.3B and total debt of $2.0B, which brings its debt-to-equity ratio to 6.8%. Its total assets and total liabilities are $37.4B and $8.1B respectively. Regeneron Pharmaceuticals's EBIT is $4.1B making its interest coverage ratio -6.7. It has cash and short-term investments of $9.8B.
Anahtar bilgiler
6.8%
Borç/özkaynak oranı
US$1.98b
Borç
| Faiz karşılama oranı | -6.7x |
| Nakit | US$9.80b |
| Eşitlik | US$29.33b |
| Toplam yükümlülükler | US$8.12b |
| Toplam varlıklar | US$37.44b |
Son finansal sağlık güncellemeleri
Is Regeneron Pharmaceuticals (NASDAQ:REGN) Using Too Much Debt?
Sep 09
These 4 Measures Indicate That Regeneron Pharmaceuticals (NASDAQ:REGN) Is Using Debt Reasonably Well
May 21These 4 Measures Indicate That Regeneron Pharmaceuticals (NASDAQ:REGN) Is Using Debt Reasonably Well
Jan 31Recent updates
Regeneron: Buying A Promising Pipeline At A Fair Price (Rating Upgrade)
Nov 04Amgen Biosimilar And EYLEA Patent Dispute: What It Means For Regeneron Investors
Sep 25Is Regeneron Pharmaceuticals (NASDAQ:REGN) Using Too Much Debt?
Sep 09Regeneron Stock: Valuation Now Demands More Growth
Aug 26Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Intrinsic Value Is Potentially 81% Above Its Share Price
Aug 22Risks To Shareholder Returns Are Elevated At These Prices For Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Aug 04Regeneron's Robust Pipeline And Financial Health Signal Continued Growth
Aug 02Regeneron: Downgrading My Outlook To 'Hold' Ahead Of Q2 Earnings
Jul 11Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) CEO Compensation Looks Acceptable To Us And Here's Why
Jun 08These 4 Measures Indicate That Regeneron Pharmaceuticals (NASDAQ:REGN) Is Using Debt Reasonably Well
May 21Regeneron: Dissecting The First Quarter Results And Regulatory Setbacks
May 06Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Popularity With Investors Is Under Threat From Overpricing
Apr 30Is There An Opportunity With Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) 47% Undervaluation?
Apr 10Regeneron's Triple Threat: Eylea, Libtayo, And Dupixent Dominate
Mar 26Regeneron Pharmaceuticals' (NASDAQ:REGN) Conservative Accounting Might Explain Soft Earnings
Feb 16Regeneron Pharmaceuticals: Time To Change My Strategy After Encouraging Q4 2024
Feb 10Regeneron's Push Into Obesity, Q4 2023 Earnings Review
Feb 02These 4 Measures Indicate That Regeneron Pharmaceuticals (NASDAQ:REGN) Is Using Debt Reasonably Well
Jan 31Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: REGN's short term assets ($19.3B) exceed its short term liabilities ($3.7B).
Uzun Vadeli Yükümlülükler: REGN's short term assets ($19.3B) exceed its long term liabilities ($4.5B).
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: REGN has more cash than its total debt.
Borcun Azaltılması: REGN's debt to equity ratio has increased from 0% to 6.8% over the past 5 years.
Borç Kapsamı: REGN's debt is well covered by operating cash flow (214.1%).
Faiz Kapsamı: REGN earns more interest than it pays, so coverage of interest payments is not a concern.